Progress and problems with the use of viral vectors for gene therapy
The DOI matches its Crossref record; 124 of the 124 references it cites were found in a registry or an index.
Abstract
Gene therapy has a history of controversy. Encouraging results are starting to emerge from the clinic, but questions are still being asked about the safety of this new molecular medicine. With the development of a leukaemia-like syndrome in two of the small number of patients that have been cured of a disease by gene therapy, it is timely to contemplate how far this technology has come, and how far it still has to go.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In all cases of leukemia, the SCID X-1 correcting gene had inserted into the patient genome within or near tumor-promoting genes and caused transcriptional activation (Check, 2002; Kaiser, 2003; Thomas et al., 2003).”
From Delivering CRISPR: a review of the challenges and approaches (2018) · cites this paper as Thomas et al., 2003
Citations
Cites
Gene Therapy of Human Severe Combined Immunodeficiency (SCID)-X1 Disease
Cavazzana-Calvo, M., Hacein-Bey, S., Basile, G. D. S., Gross, F., Yvon, E., Nusbaum, P., Selz, F., Hue, C., Certain, S., Casanova, J.-L., et al. (2000) · Science · doi:10.1126/science.288.5466.669 · Cited by 2,167 · cited 1×
“Recent evidence from a number of separate studies has challenged our perceptions about the risks of using integrating retrovirus vectors for certain types of gene therap”
BackgroundA serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency
Hacein-Bey-Abina, S., von Kalle, C., Schmidt, M., Le Deist, F., Wulffraat, N., McIntyre, E., Radford, I., Villeval, J.-L., Fraser, C. C., Cavazzana-Calvo, M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejm200301163480314 · Cited by 1,867 · cited 1×
“Recent evidence from a number of separate studies has challenged our perceptions about the risks of using integrating retrovirus vectors for certain types of gene therap”
BackgroundHIV-1 Integration in the Human Genome Favors Active Genes and Local Hotspots
Schröder, A. R. W., Shinn, P., Chen, H., Berry, C., Ecker, J. R., & Bushman, F. (2002) · Cell · doi:10.1016/s0092-8674(02)00864-4 · Cited by 1,832
Self-Inactivating Lentivirus Vector for Safe and Efficient In Vivo Gene Delivery
Zufferey, R., Dull, T., Mandel, R. J., Bukovsky, A., Quiroz, D., Naldini, L., & Trono, D. (1998) · Journal of Virology · doi:10.1128/jvi.72.12.9873-9880.1998 · Cited by 1,815
An Adenovirus Mutant That Replicates Selectively in p53- Deficient Human Tumor Cells
Bischoff, J. R., Kirn, D. H., Williams, A., Heise, C., Horn, S., Muna, M., Ng, L., Nye, J. A., Sampson-Johannes, A., Fattaey, A., et al. (1996) · Science · doi:10.1126/science.274.5286.373 · Cited by 1,760
Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy
Gao, G.-P., Alvira, M. R., Wang, L., Calcedo, R., Johnston, J., & Wilson, J. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182412299 · Cited by 1,520 · cited 1×
“AAV vector genomes flanked by AAV2 inverted terminal repeats (ITRs) have also been successfully cross-packaged in the capsids of alternative serotypes, creating a portfolio of pseudotypes with different specificitie”
BackgroundRubinson, D. A., Dillon, C. P., Kwiatkowski, A. V., Sievers, C., Yang, L., Kopinja, J., Rooney, D. L., Zhang, M., Ihrig, M. M., McManus, M. T., et al. (2003) · Nature Genetics · doi:10.1038/ng1117 · Cited by 1,501
Naldini, L., Blömer, U., Gage, F. H., Trono, D., & Verma, I. M. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.21.11382 · Cited by 1,499 · cited 1×
“They have proven to be effective tools for gene delivery to the central nervous system (CNS), generating long-term gene expression in the absence of inflammatio”
BackgroundViral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics
Kay, M. A., Glorioso, J. C., & Naldini, L. (2001) · Nature Medicine · doi:10.1038/83324 · Cited by 1,342
Self-citationKordower, J. H., Emborg, M. E., Bloch, J., Ma, S. Y., Chu, Y., Leventhal, L., McBride, J., Chen, E.-Y., Palfi, S., Roitberg, B. Z., et al. (2000) · Science · doi:10.1126/science.290.5492.767 · Cited by 1,251 · cited 1×
“gov/htbin-post/Omim/dispmim?168600">Parkinson disease”
Cited by
Items 101–200 of 1,002
Nanoparticles Mimicking Viral Surface Topography for Enhanced Cellular Delivery
Niu, Y., Yu, M., Hartono, S. B., Yang, J., Xu, H., Zhang, H., Zhang, J., Zou, J., Dexter, A., Gu, W., et al. (2013) · Advanced Materials · doi:10.1002/adma.201302737 · Cited by 207
Transplantation of Cord Blood Mesenchymal Stem Cells as Spheroids Enhances Vascularization
Bhang, S. H., Lee, S., Shin, J.-Y., Lee, T.-J., & Kim, B.-S. (2012) · Tissue Engineering Part A · doi:10.1089/ten.tea.2011.0640 · Cited by 204
“Nevertheless, these approaches have limitations, such as the spatiotemporal release control for the growth factor codelivery,(14) and a potential risk of immunogenicity or mutagenesis in case of the genetic modifications.(15) As an alternative approach, we recently reported that grafting adipose-derived mesenchymal st…”
BackgroundPandey, S., Gao, X. D., Krasnow, N. A., McElroy, A., Tao, Y. A., Duby, J. E., Steinbeck, B. J., McCreary, J., Pierce, S. E., Tolar, J., et al. (2024) · Nature Biomedical Engineering · doi:10.1038/s41551-024-01227-1 · Cited by 203
Zhang, W., Taheri-Ledari, R., Ganjali, F., Mirmohammadi, S. S., Qazi, F. S., Saeidirad, M., KashtiAray, A., Zarei-Shokat, S., Tian, Y., & Maleki, A. (2023) · RSC Advances · doi:10.1039/d2ra06888e · Cited by 200
Gene therapy for rheumatic diseases
Evans, C. H., Ghivizzani, S. C., Kang, R., Muzzonigro, T., Wasko, M. C., Herndon, J. H., & Robbins, P. D. (1999) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199901)42:1<1::aid-anr1>3.0.co;2-4 · Cited by 198
“Viral vectors are reviewed in reference [24].”
Physical Non-Viral Gene Delivery Methods for Tissue Engineering
Mellott, A. J., Forrest, M. L., & Detamore, M. S. (2013) · Annals of Biomedical Engineering · doi:10.1007/s10439-012-0678-1 · Cited by 196
Leal, C., Bouxsein, N. F., Ewert, K. K., & Safinya, C. R. (2010) · Journal of the American Chemical Society · doi:10.1021/ja1059763 · Cited by 195
Growth factor delivery for oral and periodontal tissue engineering
Kaigler, D., Cirelli, J. A., & Giannobile, W. V. (2006) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.3.5.647 · Cited by 193
“Retrovirus, lentivirus and adeno-associated virus have their genomes integrated into host chromosomes and are more indicated for applications requiring persistent and stable genetic changes [145].”
BackgroundWang, X., Zhang, H., Bai, M., Ning, T., Ge, S., Deng, T., Liu, R., Zhang, L., Ying, G., & Ba, Y. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.01.001 · Cited by 192
Progress and problems with the use of suicide genes for targeted cancer therapy
Karjoo, Z., Chen, X., & Hatefi, A. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.05.009 · Cited by 192
“As useful as this feature is for a long term expression of transgenes, the risk of insertional mutagenesis remains to be addressed [52].”
Polyplex Evolution: Understanding Biology, Optimizing Performance
Hall, A., Lächelt, U., Bartek, J., Wagner, E., & Moghimi, S. M. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.01.024 · Cited by 192
“Consequently, these complications placed a greater emphasis on the development of synthetic non-viral vectors to act as a safer option for the delivery of nucleic acid medicines.(6) Recent years havewitnessed the development of amyriad of synthetic non-viral vectors; however, as a result of various complications, the…”
BackgroundCardiovascular drug delivery with ultrasound and microbubbles
Unger, E., Porter, T., Lindner, J., & Grayburn, P. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.01.012 · Cited by 189
“Viruses, however, can be immunogenic and cause allergic reaction [105].”
Gene therapy for neurodegenerative disorders: advances, insights and prospects
Chen, W., Hu, Y., & Ju, D. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.01.015 · Cited by 187
Phenylketonuria: a review of current and future treatments.
Hafid, N. A., & Christodoulou, J. (2015) · PubMed · doi:10.3978/j.issn.2224-4336.2015.10.07 · Cited by 185
“Furthermore, the vectors do not carry any viral genes, and therefore elicit minimal immune responses (89).”
BackgroundCell engineering with microfluidic squeezing preserves functionality of primary immune cells in vivo
DiTommaso, T., Cole, J. M., Cassereau, L., Buggé, J. A., Hanson, J. L. S., Bridgen, D. T., Stokes, B. D., Loughhead, S. M., Beutel, B. A., Gilbert, J. B., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1809671115 · Cited by 185
Chemical vectors for gene delivery: uptake and intracellular trafficking
Pichon, C., Billiet, L., & Midoux, P. (2010) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2010.07.003 · Cited by 182
“But with viral vectors, severe fatal adverse events of including acute immune response and insertion mutagenesis have occurred during gene therapy clinical trials raising serious safety concerns about the use of viral vectors [1,2].”
BackgroundThe CRF Family of Neuropeptides and their Receptors - Mediators of the Central Stress Response
Dedic, N., Chen, A., & Deussing, J. M. (2018) · Current Molecular Pharmacology · doi:10.2174/1874467210666170302104053 · Cited by 182
Shelton, M., Metz, J., Liu, J., Carpenedo, R. L., Demers, S.-P., Stanford, W. L., & Skerjanc, I. S. (2014) · Stem Cell Reports · doi:10.1016/j.stemcr.2014.07.001 · Cited by 182
“3 j 516–529 j September 9, 2014 j a2014 The A cells (MPC) for clinical applications due to the inefficiency of differentiation and the use of viral vectors and potential insertional mutations (Thomas et al., 2003).”
BackgroundLin, C., Zhong, Z., Lok, M. C., Jiang, X., Hennink, W. E., Feijen, J., & Engbersen, J. F. J. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.09.009 · Cited by 182
Genetic medicines: treatment strategies for hereditary disorders
O'Connor, T. P., & Crystal, R. G. (2006) · Nature Reviews Genetics · doi:10.1038/nrg1829 · Cited by 180
“For readers who are interested in details of the design, production, function and trafficking of gene-transfer vectors, several reviews are availabl”
BackgroundLimitations in the Design of Chimeric Antigen Receptors for Cancer Therapy
Stoiber, S., Cadilha, B. L., Benmebarek, M.-R., Lesch, S., Endres, S., & Kobold, S. (2019) · Cells · doi:10.3390/cells8050472 · Cited by 180
“In both cases, the transgene is integrated stably into the genome, which makes this approach suitable for the long-term genetic modification of cells [115].”
BackgroundBiodegradable Polymers for Gene-Delivery Applications
Chen, C.-K., Huang, P.-K., Law, W.-C., Chu, C.-H., Chen, N.-T., & Lo, L.-W. (2020) · International Journal of Nanomedicine · doi:10.2147/ijn.s222419 · Cited by 180
Kustikova, O. S., Wahlers, A., Kühlcke, K., Stähle, B., Zander, A. R., Baum, C., & Fehse, B. (2003) · Blood · doi:10.1182/blood-2003-05-1424 · Cited by 179
“0 (1-3) NA 3 2 4 1 6 1 9 3 12 3 CD34 E (2 ) 2 52.”
Correlation of the cytotoxic effects of cationic lipids with their headgroups
Cui, S., Wang, Y., Gong, Y., Lin, X., Zhao, Y., Zhi, D., Zhou, Q., & Zhang, S. (2018) · Toxicology Research · doi:10.1039/c8tx00005k · Cited by 179
Biomaterials for mRNA delivery
Islam, M. A., Reesor, E. K. G., Xu, Y., Zope, H. R., Zetter, B. R., & Shi, J. (2015) · Biomaterials Science · doi:10.1039/c5bm00198f · Cited by 176
Bacteria as vectors for gene therapy of cancer
Baban, C. K., Cronin, M., O’Hanlon, D., O’Sullivan, G. C., & Tangney, M. (2010) · Bioengineered Bugs · doi:10.4161/bbug.1.6.13146 · Cited by 175
“From a safety point of view, many viruses are toxic and elicit systemic inflammatory reactions and clinical trials have highlighted safety fears over viral vector integration (which has resulted in cases of leukemia) and fatal immune responses leading to an increased interest in non-viral systems.(15,18) Bacteria as g…”
BackgroundZhu, Z., Zhai, Y., Hao, Y., Wang, Q., Han, F., Zheng, W., Hong, J., Cui, L., Jin, W., Ma, S., et al. (2022) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12255 · Cited by 175
“Nonspecific cytotoxicity, poor biocompatibility and low delivery efficiency have been reported in the traditional nano-delivery systems (Thomas et al., 2003).”
BackgroundNon-Viral in Vitro Gene Delivery: It is Now Time to Set the Bar!
Bono, N., Ponti, F., Mantovani, D., & Candiani, G. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12020183 · Cited by 176
“, oncogenic potential), cytotoxicity, and immunogenicity [38,39].”
BackgroundBiosafety Features of Lentiviral Vectors
Schambach, A., Zychlinski, D., Ehrnstroem, B., & Baum, C. (2013) · Human Gene Therapy · doi:10.1089/hum.2012.229 · Cited by 173
“The original rationale for the development of lentiviralgene vectors mostly concerned their ability to transduce a large variety of nondividing cells (Naldini et al., 1996; Thomas et al., 2003; Naldini, 2011).”
MicroRNA: an Emerging Therapeutic Target and Intervention Tool
Liu, Z., Sall, A., & Yang, D. (2008) · International Journal of Molecular Sciences · doi:10.3390/ijms9060978 · Cited by 173
“As a major blockage for clinical gene therapy is the occurrence of transgene-specific immunity, which comes from the expression of transgenes in professional antigen-presenting cells [102, 103].”
BackgroundWarnock, J. N., Daigre, C., & Al-Rubeai, M. (2011) · Methods in Molecular Biology · doi:10.1007/978-1-61779-095-9_1 · Cited by 135
“While nonviral methods are generally considered to be safer than viral transduction (1, 2), the production yield for plasmid DNA needs to be increased, and costs need to be decreased to make this a commercially viable gene-delivery method (3, 4); in addition, the gene transfer efficiency has to be improved.”
BackgroundLian, X., Erazo-Oliveras, A., Pellois, J.-P., & Zhou, H.-C. (2017) · Nature Communications · doi:10.1038/s41467-017-02103-0 · Cited by 172
Challenges in carrier‐mediated intracellular delivery: moving beyond endosomal barriers
Stewart, M. P., Lorenz, A., Dahlman, J., & Sahay, G. (2016) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1377 · Cited by 155
Non-coding RNAs: the new central dogma of cancer biology
Saw, P. E., Xu, X., Chen, J., & Song, E.-W. (2021) · Science China Life Sciences · doi:10.1007/s11427-020-1700-9 · Cited by 171
“genesis, immunogenicity, and broad tissue tropism (Thomas et al., 2003).”
BackgroundIngato, D., Lee, J. U., Sim, S. J., & Kwon, Y. J. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.09.016 · Cited by 171
Acid-Degradable Cationic Dextran Particles for the Delivery of siRNA Therapeutics
Cohen, J. L., Schubert, S., Wich, P. R., Cui, L., Cohen, J. A., Mynar, J. L., & Fréchet, J. M. J. (2011) · Bioconjugate Chemistry · doi:10.1021/bc100542r · Cited by 156
Concepts in gene therapy for cartilage repair
Steinert, A. F., Nöth, U. A., & Tuan, R. S. (2008) · Injury · doi:10.1016/j.injury.2008.01.034 · Cited by 171
A Comprehensive Review on Intracellular Delivery
Rad, D. M., Rad, M. A., Bazaz, S. R., Kashaninejad, N., Jin, D., & Warkiani, M. E. (2021) · Advanced Materials · doi:10.1002/adma.202005363 · Cited by 171
Hultquist, J. F., Schumann, K., Woo, J. M., Manganaro, L., McGregor, M. J., Doudna, J., Simon, V., Krogan, N. J., & Marson, A. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.09.080 · Cited by 170
Tailored carbon nanotubes for tissue engineering applications
Veetil, J. V., & Ye, K. (2009) · Biotechnology Progress · doi:10.1002/btpr.165 · Cited by 169
“This approach can potentially induce undesirable immune responses, inflammation and even oncogenic effects.(55) Hence, a variety of nonviral vectors such as liposomes, cationic lipids, polymers have been developed to replace the viral vector-mediated gene delivery.”
BackgroundBouxsein, N. F., McAllister, C. S., Ewert, K. K., Samuel, C. E., & Safinya, C. R. (2007) · Biochemistry · doi:10.1021/bi062138l · Cited by 169
“and integration issues sometimes associated with viral techniques (24), they are not optimized to achieve the delivery efficiency seen with virus-based vectors.”
BackgroundNanoparticles for cancer gene therapy: Recent advances, challenges, and strategies
Wang, K., Kievit, F. M., & Zhang, M. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.10.016 · Cited by 169
Green, J. J., Zugates, G. T., Tedford, N. C., Huang, Y. ‐., Griffith, L. G., Lauffenburger, D. A., Sawicki, J. A., Langer, R., & Anderson, D. G. (2007) · Advanced Materials · doi:10.1002/adma.200700371 · Cited by 168
Baculovirus Vectors for Gene Therapy
Hu, Y. (2006) · Advances in virus research · doi:10.1016/s0065-3527(06)68008-1 · Cited by 168
“Furthermore, the preexisting immunity to human AAV vectors is comparable to that of adenoviral vectors (Thomas et al., 2003).”
InfluentialA versatile family of degradable non-viral gene carriers based on hyperbranched poly(ester amine)s
Zhong, Z., Song, Y., Engbersen, J. F. J., Lok, M. C., Hennink, W. E., & Feijén, J. (2005) · Journal of Controlled Release · doi:10.1016/j.jconrel.2005.06.022 · Cited by 167
Biodegradable Polymeric Vectors for Gene Delivery to Human Endothelial Cells
Green, J. J., Shi, J., Chiu, E., Leshchiner, E. S., Langer, R., & Anderson, D. G. (2006) · Bioconjugate Chemistry · doi:10.1021/bc0600968 · Cited by 166
Ewert, K. K., Zidovska, A., Ahmad, A. K., Bouxsein, N. F., Evans, H. M., McAllister, C. S., Samuel, C. E., & Safinya, C. R. (2010) · Topics in current chemistry · doi:10.1007/128_2010_70 · Cited by 166
“Synthetic (non-viral) vectors have garnered much interest due to their nonimmunogenicity and their ability to transfer very large DNA pieces into cells (which is not feasible with viral vectors) [19].”
Nanomaterial-Enabled Cancer Therapy
Quader, S., & Kataoka, K. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.04.026 · Cited by 165
“Several systems, broadly categorized as viral and nonviral vectors, have been developed to enable the cellular delivery of genetic materials.(36) Favorably, a number of viral gene carriers have reached clinical practice due to their high transfection efficiency.”
BackgroundLin, C., Blaauboer, C.-J., Timoneda, M. M., Lok, M. C., van Steenbergen, M., Hennink, W. E., Zhong, Z., Feijen, J., & Engbersen, J. F. J. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.11.012 · Cited by 164
Non-cytotoxic polymer vesicles for rapid and efficient intracellular delivery
Lomas, H., Massignani, M., Abdullah, K. A., Canton, I., Lo Presti, C., MacNeil, S., Du, J., Blanazs, A., Madsen, J., Armes, S. P., et al. (2008) · Faraday Discussions · doi:10.1039/b717431d · Cited by 164
Lopez-Bertoni, H., Kozielski, K. L., Rui, Y., Lal, B., Vaughan, H., Wilson, D. R., Mihelson, N., Eberhart, C. G., Laterra, J., & Green, J. J. (2018) · Nano Letters · doi:10.1021/acs.nanolett.8b00390 · Cited by 164
Zhang, D., Atochina-Vasserman, E. N., Maurya, D. S., Huang, N., Xiao, Q., Ona, N., Liu, M., Shahnawaz, H., Ni, H., Kim, K., et al. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.1c05813 · Cited by 163
Eltoukhy, A. A., Siegwart, D. J., Alabi, C. A., Rajan, J. S., Langer, R., & Anderson, D. G. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.01.046 · Cited by 163
“Despite recent clinical progress[1], concerns with the use of viral vectors, including immunogenicity, small DNA cargo capacity, and difficulty of large-scale production, have led to continued interest in the development of synthetic carriers[2].”
BackgroundNon-viral gene delivery nanoparticles based on Poly(β-amino esters) for treatment of glioblastoma
Tzeng, S. Y., Guerrero‐Cazares, H., Martinez, E. E., Sunshine, J. C., Quiñones‐Hinojosa, A., & Green, J. J. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.04.016 · Cited by 163
“Despite the vast potential of gene therapy, viral methods are plagued with safety concerns [12], while non-viral delivery vehicles often lack efficiency [13].”
Targeting cancer by transcriptional control in cancer gene therapy and viral oncolysis.
Dorer, D. E., & Nettelbeck, D. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.03.013 · Cited by 153
Jiang, L., Vader, P., & Schiffelers, R. M. (2017) · Gene Therapy · doi:10.1038/gt.2017.8 · Cited by 162
“6 Colloidal carriers are being recognized by the immune system as harmful particles, resulting in a hypersensitivity, or infusion reaction, recently described as complement (C) activation-related pseudoallergy (CARPA).”
Gene Therapy 2017: Progress and Future Directions
Keeler, A., ElMallah, M., & Flotte, T. (2017) · Clinical and Translational Science · doi:10.1111/cts.12466 · Cited by 133
“94 97 In the case of CRISPR/Cas9, a sys-tem is being used that does not occur in mammalian cells at all, as far as is currently known.”
BackgroundStrategies in the design of endosomolytic agents for facilitating endosomal escape in nanoparticles
Ahmad, A., Khan, J. M., & Haque, S. (2019) · Biochimie · doi:10.1016/j.biochi.2019.02.012 · Cited by 161
Site-directed transposon integration in human cells
Yant, S. R., Huang, Y., Akache, B., & Kay, M. A. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm089 · Cited by 150
“Retroviral vectors can reliably insert a gene into the chromosomes of a target cell (4).”
BackgroundSelf-citationExploring the potential of genome editing CRISPR-Cas9 technology
Singh, V., Braddick, D., & Dhar, P. K. (2017) · Gene · doi:10.1016/j.gene.2016.11.008 · Cited by 160
“A number of non-viral vectors including lipid nanoparticles (LNPs), liposome, polymers, conjugates, and cell-derived membrane vesicles (CMVs) (Thomas et al., 2003; Yin et al., 2014b).”
BackgroundMetal nanoparticles synthesis through natural phenolic acids
Amini, S. M., & Akbari, A. (2019) · IET Nanobiotechnology · doi:10.1049/iet-nbt.2018.5386 · Cited by 160
Gene Therapy Tools for Brain Diseases
Ingusci, S., Verlengia, G., Soukupova, M., Zucchini, S., & Simonato, M. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00724 · Cited by 158
Current trends in biologics delivery to restore intervertebral disc anabolism
Fontana, G., See, E., & Pandit, A. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.08.008 · Cited by 158
Yuan, P., Hu, Q., Tang, G., & Li, J. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.03.071 · Cited by 158
CRISPR/Cas9 technology as a potent molecular tool for gene therapy
Karimian, A., Azizian, K., Parsian, H., Rafieyan, S., Shafiei‐Irannejad, V., Kheyrollah, M., Yousefi, M., Majidinia, M., & Yousefi, B. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.27972 · Cited by 163
“Lentivirus belongs to the retroviridae family which is able to integrate into the host genome (Thomas et al., 2003).”
BackgroundPreparation of antimicrobial metallic nanoparticles with bioactive compounds
Amini, S. M. (2019) · Materials Science and Engineering C · doi:10.1016/j.msec.2019.109809 · Cited by 161
Advances in Porous Silicon–Based Nanomaterials for Diagnostic and Therapeutic Applications
Tieu, T., Alba, M., Elnathan, R., Cifuentes‐Rius, A., & Voelcker, N. H. (2018) · Advanced Therapeutics · doi:10.1002/adtp.201800095 · Cited by 157
Poking cells for efficient vector-free intracellular delivery
Wang, Y., Yang, Y., Yan, L., Kwok, S.-Y., Li, W., Wang, Z., Zhu, X. A., Zhu, G., Zhang, W., Chen, X., et al. (2014) · Nature Communications · doi:10.1038/ncomms5466 · Cited by 156
Nontoxic nanopore electroporation for effective intracellular delivery of biological macromolecules
Cao, Y., Ma, E., Cestellos-Blanco, S., Zhang, B., Qiu, R., Su, Y., Doudna, J. A., & Yang, P. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1818553116 · Cited by 147
“While viral-mediated approaches efficiently transfect DNA into various cell types, their application remains a considerable safety concern (8, 9).”
BackgroundPoly(Ethylene Glycol)–Polylactide Micelles for Cancer Therapy
Wang, J., Li, S., Han, Y., Guan, J., Chung, S., Wang, C., & Li, D. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00202 · Cited by 155
“Therefore, it is clear there is still need for further investigation to improve the delivery mechanism (Thomas et al., 2003; Ginn et al., 2013).”
BackgroundLiquid biopsy for cancer screening, patient stratification and monitoring
Brock, G., Castellanos-Rizaldos, E., Hu, L., Coticchia, C. M., & Skog, J. (2018) · Translational Cancer Research · doi:10.21037/4546 · Cited by 154
“By way of comparison, retrovirus particles with a similar size can package only around 10 kb (73), so it is likely that a single vesicle of that size carries only a limited number of transcripts.”
BackgroundKommareddy, S., & Amiji, M. M. (2007) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2006.11.005 · Cited by 154
“There are reported incidents of insertional mutagenesis during treatment in humans, and their safety is an issue [3-5].”
BackgroundA Facile Approach to Functionalize Cell Membrane-Coated Nanoparticles
Zhou, H., Fan, Z., Lemons, P. K., & Cheng, H. (2016) · Theranostics · doi:10.7150/thno.15095 · Cited by 149
“Genetic engineering is a common strategy to functionalize cells with new membrane proteins [16, 17].”
BackgroundThe Prospect of Silencing Disease Using RNA Interference
Shankar, P., Manjunath, N., & Lieberman, J. (2005) · JAMA · doi:10.1001/jama.293.11.1367 · Cited by 153
“These include efficient transduction of targeted cells, particularly of pluripotent stem cells, without inducing differentiation; sustained and efficient gene expression of transduced cells; the danger of oncogenesis from insertional mutagenesis; the risk of recombination with endogenous retroviruses; and toxicity fro…”
Recent developments in the use of adenoviruses and immunotoxins in cancer gene therapy
Yang, Z., Wang, H., Zhao, J., Peng, Y., Wang, J., Guinn, B., & Huang, L. (2007) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7701054 · Cited by 152
Chiou, G., Cherng, J., Hsu, H., Wang, M., Tsai, C., Lu, K., Chien, Y., Hung, S., Chen, Y., Wong, C.-I., et al. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.01.014 · Cited by 151
“Non-viral gene delivery, such as polymer-based gene delivery system, has been considered to be potentially safer than viral-mediated delivery [15].”
Preparation for a first-in-man lentivirus trial in patients with cystic fibrosis
Alton, E. W. F. W., Beekman, J. M., Boyd, A. C., Brand, J., Carlon, M. S., Connolly, M. M., Chan, M., Conlon, S., Davidson, H. E., Davies, J. C., et al. (2017) · Thorax · doi:10.1136/thoraxjnl-2016-208406 · Cited by 150
Tissue-specific gene delivery via nanoparticle coating
Harris, T. J., Green, J. J., Fung, P. W., Langer, R., Anderson, D. G., & Bhatia, S. N. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2009.10.012 · Cited by 150
“A key hurdle to its clinical application is the lack of safe and effective delivery systems [4,5].”
Adeno-Associated Viral Vectors and Their Redirection to Cell-Type Specific Receptors
Michelfelder, S., & Trepel, M. (2009) · Advances in genetics · doi:10.1016/s0065-2660(09)67002-4 · Cited by 151
“The biological safety and the unsatisfactory efficacy of gene transfer vectors pose significant challenges for gene therapy (Somia and Verma, 2000; Thomas et al., 2003).”
BackgroundMicroRNAs in cancer biology and therapy: Current status and perspectives
Price, C., & Chen, J. (2014) · Genes & Diseases · doi:10.1016/j.gendis.2014.06.004 · Cited by 137
“The nanoparticle delivery method appears attractive because it avoids several of the concerns used for viral delivery systems.(107) The nanoparticle delivery method has been shown to hold great potential.”
BackgroundMethodPeptide Self-Assembled Nanostructures for Drug Delivery Applications
Fan, T., Yu, X., Shen, B. Q., & Sun, L. (2017) · Journal of Nanomaterials · doi:10.1155/2017/4562474 · Cited by 149
“For example, the nanocarriers for gene drug delivery should be improved through different perspectives including toxicity, immunogenic response, and poor uptake into cells and the nucleus [125, 126].”
BackgroundPlasmid DNA Delivery: Nanotopography Matters
Song, H., Yu, M., Lu, Y., Gu, Z., Yang, Y., Zhang, M., Fu, J., & Yu, C. (2017) · Journal of the American Chemical Society · doi:10.1021/jacs.7b08974 · Cited by 149
Using artificial microRNA sponges to achieve microRNA loss-of-function in cancer cells
Tay, F. C., Lim, J. K., Zhu, H., Hin, L. C., & Wang, S. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.05.010 · Cited by 148
Everything that Glitters Isn't Gold: A Critical Review of Postnatal Neural Precursor Analyses
Breunig, J. J., Arellano, J. I., Macklis, J. D., & RAKIC, P. T. (2007) · Cell stem cell · doi:10.1016/j.stem.2007.11.008 · Cited by 149
siRNA Delivery to the lung: What's new?
Merkel, O. M., Rubinstein, I., & Kissel, T. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.05.018 · Cited by 132
“And although viral vectors bear advantages in regards to cellular delivery of nucleic acids, their safety concerning toxicity, immunogenicity, tumorigenicity as well as uncontrolled virus replication [41] and their reproducible manufacturing are challenges for clinical applications.”
Effect of chemical functionalities in poly(amido amine)s for non-viral gene transfection
Lin, C., & Engbersen, J. F. J. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.06.022 · Cited by 149
A future for transgenic livestock
Clark, A., & Whitelaw, B. (2003) · Nature Reviews Genetics · doi:10.1038/nrg1183 · Cited by 147
“Lentivectors are being developed for human gene therapy 54 and so they are already undergoing extensive safety testing, particularly with respect to their replication-defective nature.”
BackgroundHydrophilic Co@Au Yolk/Shell Nanospheres: Synthesis, Assembly, and Application to Gene Delivery
Lü, Y., Zhao, Y., Yu, L., Dong, L., Shi, C., Hu, M., Xu, Y., Wen, L., & Yu, S. (2010) · Advanced Materials · doi:10.1002/adma.200903298 · Cited by 146
Cho, H. Y., Srinivasan, A., Hong, J., Hsu, E., Liu, S., Shrivats, A., Kwak, D., Bohaty, A. K., Paik, H.-J., Hollinger, J. O., et al. (2011) · Biomacromolecules · doi:10.1021/bm2006455 · Cited by 136
Boissel, L., Betancur, M., Lu, W., Wels, W. S., Marino, T., Van Etten, R. A., & Klingemann, H. (2012) · Leukemia & Lymphoma · doi:10.3109/10428194.2011.634048 · Cited by 139
“Despite their high transduction efficiency, however, any viral construct carries the risk of insertional mutagenesis and is not preferred for application in humans [26].”
BackgroundVirus‐Inspired Polymer for Efficient In Vitro and In Vivo Gene Delivery
Cheng, Y., Yumul, R., & Pun, S. H. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201605958 · Cited by 146
Dufès, C., Keith, W. N., Bilsland, A. E., Proutski, I., Uchegbu, I. F., & Schätzlein, A. G. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4402 · Cited by 146
“The clinical realisation of the potential benefits of gene therapy, in particular for cancer, remains limited, partly because of the challenges of systemic delivery (1, 2).”
BackgroundNanomaterials for Therapeutic RNA Delivery
Han, X., Mitchell, M. J., & Nie, G. (2020) · Matter · doi:10.1016/j.matt.2020.09.020 · Cited by 135
Sleeping Beauty Transposon‐Mediated Gene Therapy for Prolonged Expression
Hackett, P. B., Ekker, S. C., Largaespada, D. A., & McIvor, R. S. (2005) · Advances in genetics · doi:10.1016/s0065-2660(05)54009-4 · Cited by 145
Retroviral Gene Therapy: Safety Issues and Possible Solutions
Yi, Y., Hahm, S. H., & Lee, K. (2005) · Current Gene Therapy · doi:10.2174/1566523052997514 · Cited by 145
O’Connor, R. M., Dinan, T. G., & Cryan, J. F. (2011) · Molecular Psychiatry · doi:10.1038/mp.2011.162 · Cited by 146
Escaping the endosome: assessing cellular trafficking mechanisms of non-viral vehicles
Xu, E., Saltzman, W. M., & Piotrowski-Daspit, A. S. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.05.038 · Cited by 144
Nanomaterial mediated optogenetics: opportunities and challenges
Huang, K., Dou, Q., & Loh, X. J. (2016) · RSC Advances · doi:10.1039/c6ra11289g · Cited by 138
Santos-Carballal, B., Fernández, E. F., & Goycoolea, F. M. (2018) · Polymers · doi:10.3390/polym10040444 · Cited by 142
“Initial approaches, which involved the direct administration of recombinant CFTR, based on conventional DNA delivery to the airway, have not been successful for several reasons, such as immunogenicity or the limited DNA packaging capacity of the vector [273,274].”
BackgroundZhou, J. J., Sun, L., Wang, L., Liu, Y., Li, J., Li, J., Li, J., & Yang, H. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201813665 · Cited by 142
Metadata
- Authors
- Thomas, C. E., Ehrhardt, A., & Kay, M. A.
- Affiliations
- Stanford Medicine (US)
- Corresponding author
- Kay, Mark A.
- Venue
- Nature Reviews Genetics
- Published
- 2003-05-01
- Volume
- 4
- Issue
- 5
- Pages
- 346-358
- ISSN
- 1471-0056 (ISSN-L)
- 1471-0064
- OpenAlex
- W2014356856
- Cited by
- 2,501
- References
- 124
- Citations by year
- 2026: 41 · 2025: 59 · 2024: 110 · 2023: 98 · 2022: 109 · 2021: 116 · 2020: 151 · 2019: 153 · 2018: 150 · 2017: 168 · 2016: 142 · 2015: 143 · 2014: 148 · 2013: 122 · 2012: 109
- FWCI
- 8.46
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Genetics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- University of Pennsylvania
- Hospital for Sick Children
- National Institutes of Health
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- gene therapy, viral vectors, clinical gene therapy, gene therapy safety, retroviral vectors, clinical trials
- MeSH terms
- Dependovirus, Adenoviridae, Defective Viruses, Genetic Vectors, Humans, Neoplasms, Retroviridae, Viruses, Genetic Therapy, Lentivirus, Simplexvirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.